Abstract: An assembly comprising an absorber of near infrared (NIR) light having an optical absorption cross section not lower than 100 nm2 covalently linked to an inhibitor of carbonic anhydrase (CA), process for its preparation and its use to hyperthermally target tumours or for treating other conditions in which the CA activity is involved is disclosed.

Abstract: The invention discloses the use of coenzyme Q10 for preventing or inhibiting apoptosis in cutaneous or adipose cells and tissues, and pharmaceutical compositions containing coenzyme Q10 for the treatment of transplanted tissues.

Abstract: The present invention relates to the use of Coenzyme Q10 or functionally equivalent derivatives thereof, through topical or systemic administration, for the prevention, the treatment and/or attenuation of degenerative ocular pathologies, said pathologies being of an heredofamilial, inflammatory, dysmetabolic, senile age-related nature, the degenerative process deriving from apoptotic events caused by hypoxia or other detrimental stimuli due to ischemia or to the lack of trophic factors.

Abstract: In the treatment of ophthalmologic pathologies in general and in particular in the treatment and prevention of side-effects on eye following photorefractive therapy (PRK), laser-assisted in situ keratomileusis (LASIK) and exposure to solar light and ultraviolet radiation, ubiquinone Q10 is utilized in a collyrium pharmaceutical preparation for ocular topical administration thereof.

Abstract: In the treatment of ophthalmologic pathologies in general and in particular in the treatment and prevention of side-effects on eye following photorefractive therapy (PRK), laser-assisted in situ keratomileusis (LASIK) and exposure to solar light and ultraviolet radiation, ubiquinone Q10 is utilized in a collyrium pharmaceutical preparation for ocular topical administration thereof.

Abstract: The present invention relates to the use of Coenzyme Q10 or functionally equivalent derivatives thereof, through topical or systemic administration, for the prevention, the treatment and/or attenuation of degenerative ocular pathologies, said pathologies being of an heredofamilial, inflammatory, dysmetabolic, senile age-related nature, the degenerative process deriving from apoptotic events caused by hypoxia or other detrimental stimuli due to ischemia or to the lack of trophic factors.

Abstract: A chimeric bcl-2/IgH antisense transcript that hybridizes with the pre-mRNA of a hybrid gene in t(14;18) translocated cells.An ODN directed to complement any region of the above mentioned antisense transcript and the use thereof for diagnostic or therapeutic purposes.

Abstract: Antisense oligonucleotides optionally stabilized with phosphorotioate residues or analogues, or modified in the whole sugar-phosphate backbone--complementary to the human urokinase receptor messenger RNA--are able to prevent invasiveness of neoplastic cells by inhibiting the overexpression of the receptor itself, directly responsible of the invasive phenotype. Said oligomers are useful as medicaments for the treatment of primary and secondary neoplasias as well as of other pathologies wherein the urokinase receptor gene overexpression is a pathogenic event.